Patent 11987641 was granted and assigned to Janssen Biotech on May, 2024 by the United States Patent and Trademark Office.
Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.